The creation of onepharm was triggered by the desire of its parent company, AVIR Green Hills Biotechnology to divest itself of its drug development business and to focus entirely on vaccine development [REF].
Early in 2006 onepharm secured an EUR 2.7 million grant in funding from the Vienna Business Agency's Center for Innovation and Technology, as part of a collaboration with the University of Natural Resources and Applied Life Sciences Vienna and the Vienna University of Technology.